In 2025, the global clinical research landscape is defined by resilience, innovation, and accelerated activity, marking a distinct recovery and resurgence following recent years of slowdown. At the forefront of this transformation is the Asia-Pacific (APAC) region, where countries like China, South Korea, Japan, and most notably, India, are driving significant growth. For global pharmaceutical and biotechnology companies, conducting clinical trials in India has moved from a strategic option to a critical necessity, cementing the country’s status as a formidable global innovation powerhouse.
As a specialized Clinical Site Management Organization (CSMO), we recognise that India’s current position reflects both powerful market forces and deliberate national efforts to enhance quality, infrastructure, and regulatory efficiency. India is poised for a period of robust expansion, backed by massive investments in early-stage research capacity and the rapid adoption of patient-centric digital models.
The Global Resurgence and India’s Ascent in 2025
The first half of 2025 has been characterized by a clear increase in global clinical trial initiations, signalling a strong shift from the slower pace observed in recent years. This worldwide rebound is supported by stronger funding for biotech initiatives, fewer trial cancellations, and processes that move quickly from the planning stage to study commencement. Overall, the robust activity captured in the first half of 2025 brings activity levels back to those seen in 2021 and surpasses pre-pandemic figures.
Geographically, the Asia-Pacific region is the most potent driver of this increased activity. When comparing the second quarter (Q2) of 2024 to Q2 2025, India, along with China, South Korea, and Japan, ranked among the global top five countries experiencing the highest growth in trial volume.
India’s Dominant Market Position
India’s growth trajectory has been exceptionally steep. The country has rapidly expanded its footprint, positioning itself as the third-largest destination for conducting clinical trials globally as of 2024. This ranking is underscored by an impressive Compound Annual Growth Rate (CAGR) of 80% since 2019.
The sheer volume of new activity highlights this momentum: approximately 18,000 new clinical trials were registered in India in 2024, marking a substantial 50% increase from the prior year. The India clinical trials market is currently valued at USD 1.42 billion in 2024 and is forecast to grow at a strong CAGR of 8.0% from 2025 to 2030. This expansion is driven by the growing biotechnology and pharmaceutical sectors and is attracting significant investment from global pharmaceutical leaders.
India’s Irresistible Competitive Edge
Several foundational elements make conducting clinical trials in India uniquely attractive, particularly for multinational enterprises seeking strategic advantages and robust data diversity.
1. Population Diversity and Scale
India, with its population of 1.4 billion, presents an unparalleled opportunity for clinical research. The country boasts one of the world’s most heterogeneous patient populations, offering remarkable diversity in genetic makeup, disease burden, and socioeconomic status. This diversity is increasingly critical for global trials, which often suffer from the under-representation of diverse ethnic groups. Leveraging this rich patient pool enables sponsors to enhance data diversity and improve the real-world relevance of clinical findings.
2. Cost and Operational Efficiency
A primary attraction for global pharmaceutical companies is the cost-effectiveness of conducting trials in India. The costs associated with clinical research in the country are nearly half those incurred in the United States and Europe, offering a crucial opportunity for sponsors looking to optimize their research budgets. Beyond cost savings, India benefits from a large pool of highly qualified, English-speaking investigators and research professionals, streamlining communication for global studies.
3. Critical Disease Focus Areas
The disease landscape in India offers fertile ground for clinical research, driven by the high incidence of both communicable and non-communicable diseases. This includes the increasing prevalence of “Western” lifestyle-driven illnesses such as diabetes mellitus, hypertension, and dyslipidemia.
According to market analysis, the oncology segment dominated the market in 2024 and is projected to witness the fastest CAGR over the forecast period. This urgent demand is fueled by an aging population and lifestyle changes, necessitating new targeted therapies and personalized medicine approaches. Furthermore, the autoimmune/inflammation segment is also projected to see significant growth due to the increasing prevalence of disorders like rheumatoid arthritis and inflammatory bowel diseases, alongside advances in biological therapies.
Historically, India has also shown a relatively higher percentage of trials focused on vaccines and indigenous drugs compared to other study regions, reflecting national health priorities and traditional medicine systems.
A Paradigm Shift: Decentralized Clinical Trials (DCTs) in India
The future of clinical research is digital, and India is rapidly embracing models that prioritize patient-centricity and technological innovation. The rise of Decentralized Clinical Trials (DCTs) is redefining how studies are conducted by moving some or all trial activities outside traditional clinical sites.
DCTs leverage sophisticated digital health technologies, allowing participants to engage in trials from their homes or nearby healthcare facilities using tools like telemedicine, wearable devices, smartphones, and mobile apps. This “trial-to-the-patient” approach eliminates many traditional geographical barriers.
Key Benefits Driving DCT Adoption in India
The adoption of DCTs directly addresses many historical bottlenecks that limited patient participation in India:
1. Improved Patient Access and Diversity: DCTs remove geographical barriers, making participation possible for patients in rural or underrepresented communities, thus enhancing data diversity.
2. Enhanced Patient Experience: Participants benefit from reduced travel time and fewer frequent hospital visits, leading to higher patient satisfaction and better compliance.
3. Faster Execution and Real-Time Data: Digital tools enable researchers to streamline recruitment and data capture, providing continuous, real-time insights into patient outcomes through wearables and mobile apps.
4. Cost Reduction: DCTs minimize the necessity for substantial physical infrastructure and traditional site maintenance, contributing to lower overall trial costs.
Technologies Powering the Digital Shift
Successful DCT implementation relies on specific advanced digital solutions. These include:
• eConsent Platforms: Secure and user-friendly systems that simplify the informed consent process.
• Telehealth & Video Consultations: Tools enabling remote interaction between patients and clinical staff.
• Mobile Health Apps (mHealth): Used for symptom tracking, medication reminders, and direct communication.
• Wearable Devices: Crucial for continuous monitoring of vital signs (e.g., heart rate, sleep patterns).
• ePRO (Electronic Patient-Reported Outcomes): Platforms allowing patients to digitally report side effects and quality-of-life metrics.
Regulatory bodies, including the Central Drugs Standard Control Organization (CDSCO), are actively supporting the implementation of hybrid and decentralized clinical trial models, ensuring India keeps pace with global standards of pharmaceutical innovation. India, Brazil, and South Korea are among the emerging markets embracing these innovative, accessible approaches.
Addressing the Historical Gap: The Early-Phase Renaissance
Historically, India struggled to compete in early-stage clinical research, often “shying away” from Phase I trials due to infrastructure limitations and low clinical research capacity. This necessitated Indian innovators to pursue early clinical development overseas.
For example, while the United States registered 22,543 Phase 1 trials between 1999 and 2022 on the WHO’s International Clinical Trials Registry Platform (ICTRP), India registered only 2,260 in the same period.
The Turning Point: Regulatory Reform and Phase I Growth
The narrative around early-phase clinical trials in India began changing significantly after the New Drugs and Clinical Trials Rules were introduced in 2019. This shift addressed previous regulatory uncertainties and encouraged both international confidence and indigenous innovation.
This effort is already yielding results: 60% of all first-in-human Phase I trials registered in India (1,641 trials) occurred between 2019 and 2024. Furthermore, Phase I is projected to witness the fastest CAGR of 9.7% in the India clinical trials market from 2025 to 2030, driven by an increased emphasis on establishing safety and dosage parameters for novel therapies, particularly in oncology and rare diseases.
The ICMR-Network for Phase 1 Clinical Trials (A 2025 Initiative)
In a massive governmental effort to close the capacity gap, the Indian Council of Medical Research (ICMR) established the ICMR-Network for Phase 1 Clinical Trials. This network is designed to create a robust infrastructure capable of meeting the rigorous demands of early phase studies, specifically focusing on the clinical development of leads that address national health priorities.
Key highlights of this 2025 initiative include:
• Infrastructure Development: Establishing dedicated early-phase centres equipped with state-of-the-art facilities, advanced imaging, laboratory services, and pharmacokinetics capabilities.
• Manpower Training: Investing extensively in training programs covering clinical trial design, ethical considerations, and national and international regulatory requirements.
• Support for Innovators: Extending regulatory and operational assistance to academic institutions and start-ups with limited experience in early phase drug development.
• Risk and Cost Sharing: ICMR is reducing the financial burden on innovators by sharing the costs and risks inherent in early phase clinical development.
The network identified four partnering institutions through a rigorous vetting process in 2024, and the first trials focusing on oncology, vaccines, and cell & gene therapy leads are scheduled to launch in 2025.
Beyond Phase I, the ICMR’s Indian Clinical Trial and Education Network (INTENT) is actively integrating resources and institutions currently supporting 75 sites to conduct high-quality, multicentric regulatory-compliant Phase II and Phase III trials.
Strategic Market Dynamics: What Sponsors Need in India
Understanding the current market segmentation is essential for sponsors optimizing their trial strategy in India.
Phase Distribution and Focus:
While Phase I activity is accelerating, the Phase III segment dominated the India clinical trials industry in 2024, holding a 53.3% revenue share. This dominance stems from the critical role Phase III trials play in validating new treatments with large patient populations before they receive market authorization.
By study design, interventional trials dominated the market in 2024, reflecting their widespread adoption for evaluating safety and efficacy, supported by a formal framework established by the CDSCO through the Clinical Trials Rules 2019. However, the observational trials segment is projected to grow at the fastest CAGR, fueled by the rising demand for Real-World Evidence (RWE) and less invasive, more cost-effective research methods.
The Demand for Specialized Services
As a Clinical Site Management Organization, our services align directly with the fastest-growing demands in the Indian market:
1. Patient Recruitment: This segment is projected to grow at the fastest CAGR among service types. The success of clinical trials in India hinges on effective patient recruitment, utilizing the country’s large and diverse patient base, particularly for complex areas like oncology and rare disorders. Streamlined recruitment strategies, often involving remote or virtual trials made possible by digital platforms, are reducing barriers and improving patient access.
2. Site Identification and Trial Management: Global sponsors require reliable partners to manage operations across diverse demographics and complex logistical environments. Services such as Site Identification and Clinical Trial Management Services are vital components of the overall ecosystem.
Although laboratory services held the largest revenue share in 2024 due to the necessity for accurate biomarker and genetic testing for precision medicine, the operational expertise provided by site management organizations is paramount to ensuring trial execution and data quality.
Clinical Site Management Organisation Expertise: We specialise in providing end-to-end clinical trial support, including site feasibility and selection, site start-up, and regulatory compliance in strict accordance with CDSCO requirements. Our team implements patient recruitment strategies tailored to India’s diverse demographics, ensures seamless investigator and site team coordination, and provides meticulous day-to-day trial operations management. By bridging the gap between global standards, we ensure your critical study milestones are met efficiently and ethically. Contact us for seamless site management services to leverage our expertise for your global success
References:
1. Invest India: “India’s Clinical Trials Surge: Emerging as Global Innovation Powerhouse”
2. Grand View Research: “India Clinical Trials Market Size, Share | Industry Report, 2030”
3. Abiogenesis Clinpharm: “Revolutionizing Research: How Decentralized Clinical Trials Are Shaping the Future of Drug Development”
4. Communications Medicine (Nature): “Increasing early phase clinical trials capacity in India”
5. MITCON Biopharma: “The Importance of Clinical Trials in Advancing Medical Research in 2025”
6. GlobalData: “Clinical trial initiations surge in 2025”
7. Anju Software (TA Scan): “Mid-Year 2025 Clinical Trial Wrap”
8. PMC (Perspectives in Clinical Research): “Clinical trials in India”
